Assess whether RWE can replace or only supplement an RCT (779f28)

Situation

In a biologics company planning a biosimilar pathway, disproportionate reporting signal workbook is the evidence after a site-change that invalidates stability claims. RWE evidence-strategy director has to pick RWE can replace or Only supplement an RCT for this Pharma & Life Sciences CMC and Development Pathways close using disproportionate reporting signal workbook.

Decision

RWE evidence-strategy director in a biologics company planning a biosimilar pathway must choose RWE can replace / Only supplement an RCT using disproportionate reporting signal workbook after a site-change that invalidates stability claims.

Hypotheses to test

• Authorize RWE can replace now; disproportionate reporting signal workbook already has the discriminator after a site-change that invalidates stability claims.
• Keep Only supplement an RCT in force until disproportionate reporting signal workbook is completed after a site-change that invalidates stability claims for RWE evidence-strategy director.
• Treat disproportionate reporting signal workbook as RWE can replace because both readings appear after a site-change that invalidates stability claims.
• Refuse a Pharma & Life Sciences close: RWE evidence-strategy director does not have the page RWE can replace or turns on in disproportionate reporting signal workbook.

Analysis required

• Map FDA-response timing and owner in a biologics company planning a biosimilar pathway.
• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a site-change that invalidates stability claims.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences CMC and Development Pathways file, read disproportionate reporting signal workbook against a site-change that invalidates stability claims and write the one fact that would move RWE can replace or for RWE evidence-strategy director.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / CMC and Development Pathways packet (disproportionate reporting signal workbook after a site-change that invalidates stability claims). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after a site-change that invalidates stability claims, then the two facts that force it, then the Monday action for RWE evidence-strategy director in a biologics company planning a biosimilar pathway.